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ABSTRACT 
Thromboxane A2 is a potent mediator of inflammation and platelet aggregation exerting its 
effects through the activation of a G protein-coupled receptor (GPCR), termed TP. Although 
the existence of dimers/oligomers in Class A GPCRs is widely accepted, their functional 
significance still remains controversial. Recently, we have shown that TP  and TP  homo-
/hetero-dimers interact through an interface of residues in trans-membrane domain 1 (TM1) 
whose disruption impairs dimer formation. Here, biochemical and pharmacological 
characterization of this dimer deficient mutant (DDM) in living cells indicates a significant 
impairment in its response to agonists. Interestingly, two single loss-of-function TP  
variants, namely W29C and N42S recently identified in two heterozygous patients affected 
by bleeding disorders, match some of the residues mutated in our DDM. These two naturally 
occurring variants display a reduced potency to TP agonists and are characterized by 
impaired dimer formation in transfected HEK-293 cells. These findings provide evidences 
that lack of homo-dimer formation is a crucial process for reduced TP  function in vivo, and 
might represent one molecular mechanism through which platelet TP  receptor dysfunction 
affects the patient(s) carrying these mutations. 
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1. INTRODUCTION 
The completion of the human genome project identified 7 transmembrane receptors, 
commonly referred to as G protein-coupled receptors (GPCRs), as the widest gene family [1]. 
Among the five different subfamilies, the Class A or rhodopsin-like GPCRs, to which the 
thromboxane A2 receptor (TP) belongs, is the largest [2]. Members of this receptor family 
exert a wide variety of physiological processes with alterations in GPCR function 
contributing to the development of a number of pathological processes. Consequently, more 
than 30% of the current marketed drugs target GPCRs [3], with ongoing efforts to identify 
new molecules targeting the function of these proteins. 
Membrane receptors from other families have long been known to form multimeric 
complexes, including members of the growth factor receptor family [4]. Conversely, for a 
long time GPCRs were considered to function as monomeric entities with their activation 
resulting from the stoichiometric binding of one receptor moiety to a single heterotrimeric G 
protein. Indeed, a number of biochemical and biophysical data are consistent with the ability 
of rhodopsin [5-7], or other GPCRs [8-10] to activate their cognate G proteins in a 
monomeric form. However, pharmacological data from various GPCRs are not compatible 
with such a model, and increasing evidence suggests that these receptors exist and function as 
oligomeric complexes of two or more protomers [11]. Although controversial until a few 
years ago, the formation of GPCR dimers/oligomers has now been demonstrated not only in 
ectopically transfected cells, but also in native tissues in vivo and even through the resolution 
of crystallized receptor structures [12]. In spite of these evidence and of the undisputed role 
of dimerization for Class C GPCRs [13, 14], the significance of dimerization remains 
controversial for the other classes of GPCRs [15] [16]. 
Thromboxane A2 (TxA2), a product of the oxidative metabolism of arachidonic acid, is a 
potent mediator of inflammation, a stimulator of platelet activation and aggregation, and a 
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constrictor and mediator of proliferation of vascular and airway smooth muscle cells [17, 18]. 
In humans, the TP receptor is coded from a single gene that undergoes alternative splicing. 
This gives rise to two isoforms, termed TP  (343 residues) and TP  (407 residues) which 
share identical N-terminal 328 amino acids and different C-terminal tails of 15 and 79 
aminoacids, respectively [19]. The two isoforms primarily activate Gq/11 and G12/13 
heterotrimeric G proteins, although coupling to Gs, Gi, and Gh has also been reported [19]. 
The TxA2/TP receptor exerts a key role in the cardiovascular system by triggering thrombus 
formation [20].  This has been well demonstrated through the identification of a number of 
patients suffering from hemostatic defects with impaired TP receptor function due to single 
amino acid substitutions [21-24]. TP function appears to be tightly regulated, with 
suggestions that the deleterious cardiovascular effects of TP  could be limited by hetero-
dimerization with either the TP  [25, 26] or prostacyclin IP receptor [27, 28], which have 
been shown to regulate TP  trafficking and G protein coupling. 
Different artificial systems, such as solubilization in detergents [5, 9, 29], purification and 
refolding in detergent/lipid mixed micelles [10], or incorporation into phospholipid bilayer 
[6, 7], have been used to isolate GPCR monomers thus allowing the characterization of 
receptor monomer versus dimer pharmacology. Here, we directly compare in living cells the 
pharmacology and signaling of the homo-dimeric and monomeric forms of a Class A GPCR. 
Recently, we have shown that TP  and TP  homo-/hetero-dimers are characterized by 
contacts between hydrophobic residues in transmembrane domain 1 (TM1) of both protomers 
[26]. Indeed, TM1 and TM4/5 dimers, which appear more frequently in the crystals, are the 
most plausible dimeric models [30]. The disruption of this interface by alanine replacement 
of eight amino acids (Fig. 1) facing outward in dimerization-deficient mutants (DDMs) of 
one of the two TP isoforms is sufficient to drastically impair TP -TP  hetero-dimerization 
and to significantly interfere with agonist-induced TP  endocytosis. Here, we demonstrate 
  5 
that a panel of pharmacodynamically distinct agonists show reduced potencies but similar 
efficacies in the activation of the DDM with respect to wild type (WT) TP  homo-dimer. In 
addition, these agonists maintained identical binding affinities for both DDM and WT 
receptors, suggesting a similar active receptor conformation. Strikingly, we also show here 
that two single naturally occurring mutation in TM1, W29C and N42S, that are in close 
proximity to two of the residues mutated in our DDM (W29 and L43, respectively) display a 
reduced potency to agonists accompanied by an impaired dimer formation both in ectopically 
transfected HEK-293T cells and, at least partially, in platelet membranes from patients. These 
naturally occurring mutations are associated in vitro with reduced TP receptor-stimulated 
platelet activation and in vivo bleeding disorders [23, 24]. Overall, these data suggest the 
impairment of TP dimerization as one possible molecular mechanism leading to reduced 
platelet aggregation and secretion in response to TP activators in vivo thereby affecting 
patients carrying these mutations. 
2. MATERIALS AND METHODS 
2.1 Reagents 
Cell-culture media and supplements, animal serum, antibiotics, Lipofectamine® 2000, Opti-
MEM I and molecular biology reagents were purchased from Invitrogen (Carlsbad, CA). 
Inositol-free Dulbecco’s modified Eagle’s medium (DMEM) was from ICN Pharmaceuticals 
Inc. (Costa Mesa, CA). Ultima Gold™ was from PerkinElmer Life and Analytical Sciences 
(Boston, MA), as were [5,6-3H]SQ29,548 and myo-[2-3H]inositol. U46619 ([1R-
[1 ,4 ,5 (Z),6 (1E,3S*)]]-7-[6-(3-hydroxy-1-octenyl)-2-oxabicyclo[2.2.1]hept-5-yl]-5-
heptenoic acid), I-BOP ([1S-[1 ,2 (Z),3 (1E,3S*),4 ]]-7-[3-[3-hydroxy-4-(4-
iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid), 8-isoPGF2  (8-iso 
Prostaglandin F2 ), 8-isoPGE2 (8-iso Prostaglandin E2), PTA2 (Pinane TxA2 - 9 ,11 -
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(dimethyl)methylene-15S-hydroxy-11 -deoxy-11 -methylene-thromba-5Z,13E-dien-1-oic 
acid) and SQ29,548 ([1S-[1 ,2 (Z),3 ,4 ]]-7-[3-[[2-[(phenylamino)carbonyl]-
hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) and Ramatroban (3R-
[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid) were 
from Cayman Chemical (Ann Arbor, MI). Anion exchange resin AG 1X-8 (formate form, 
200–400 mesh) and Lowry dye-binding protein reagents were from Bio-Rad (Hercules, CA). 
All other reagents of the highest purity were available from Sigma-Aldrich (St. Louis, MO).  
2.2 DNA constructs 
The generation of human TP  receptor WT, DDM, and W29C DNA constructs was 
described elsewhere [23, 26, 31]. TPtrunc was obtained using the site direct mutagenesis kit 
(statagene) following manifacturer’s instructions. Brefely TPtrunc was obtained by the 
insertion of a stop codon at the Ser57 of receptor sequence (Ser57-Stop) using specific 
primers carrying the Ser57-Stop mutation (FW: 5'- 
GCGCGGCAGGGTGGTTAGCACACGCGCTCCTCC-3'; RW: 5'- 
GGAGGAGCGCGTGTGCTAACCACCCTGCCGCGC-3'). Mutated constructs was 
checked by sanger analysis. 
The cDNA encoding for the G q was purchased from Missouri S&T cDNA Research 
Center (Rolla, MO, USA). Ultrapure plasmids for cell transfection were obtained using the 
QIAfilter Plasmid Kits (Qiagen, Hilden, Germany). 
2.3 Cell culture and transient transfections 
HEK293T host cells were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA). Cells were routinely grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 100 g/ml 
streptomycin and 20 mM HEPES buffer pH 7.4, at 37°C in a humidified atmosphere of 95% 
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air and 5% CO2. For transfection, cells were seeded onto tissue culture dishes previously 
coated with 5 g/ml poly-D-lysine, and transfected at 30–40% confluence with an optimized 
2:1 Lipofectamine 2000/DNA ratio as described previously [32]. All assays were performed 
48 hours after transfection. In co-transfection experiments with TP and G q, plasmids were 
added in a 1:5 g ratio, respectively. 
2.4 Western immunoblotting 
Transfected cells were lysed in lysis buffer containing a protease inhibitor cocktail (Sigma-
Aldrich). Equal amounts of proteins were resolved on SDS-PAGE (10% acrylamide) and 
electro-transferred to Hybond-P membrane (GE Healthcare-Amersham, Piscataway, NJ). 
Blots were incubated overnight at 4°C in TBST [10mM Tris-HCl buffer, pH 8.0, 150 mM 
NaCl, 0.1% (v/v) Tween 20] containing 5% (w/v) skimmed milk. After washing with TBST, 
membranes were incubated at 25°C for 2 h with anti-Myc antibody diluted in TBST-milk 
(Pierce, Rockford, IL). After washing in TBST, membranes were probed for 1.5 h at 25°C 
with horseradish peroxidase-conjugated goat anti-rabbit/mouse IgGs diluted in TBST-milk. 
Proteins were detected by chemiluminescence using the SuperSignal West Dura Extended 
Duration Substrate (Pierce) and visualized with Kodak Image Station 440 CF (Eastman 
Kodak Co., New Haven, CT). Band intensities were measured with the ‘gel analyzer’ 
ImageJ® plugin. 
Platelets were probed using Abcam ab85544 a rabbit polyclonal antibody against the 
carboxyl-terminal of the human TP receptor as previously described [23]. 
2.5 Radioligand binding and total inositol phosphate assays 
Receptor expression and functional activity were monitored 48 hours after transfection. 
Ligand binding characteristics were determined on confluent adherent cells performing a 
mixed-type protocol [33] with the specific receptor antagonist [3H]SQ29,548 (48 Ci/mmol) 
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as previously described [31, 32, 34]. Briefly, heterologous competition studies involved 
concentrations of the indicated unlabeled ligands ranging from 0.1 nM to 30 M against 1 
nM [3H]SQ29,54. After 30 min incubation at 25°C, reactions were stopped by medium 
aspiration, and cells were washed with ice-cold PBS containing 0.2% (w/v) BSA and lysed in 
0.5 N NaOH. Radioactivity was measured by liquid scintillation counting. Binding data were 
analyzed as described in Data and Statistical Analysis. Quantitation of the total labeled IP 
accumulation was performed using a conventional gravity flow column chromatography, as 
described previously [31, 32, 34]. Briefly, on day before assay, cells were labeled with 0.5 
Ci [myo-2-3H]inositol (17 Ci/mmol) for 18-20 hours in serum- and inositol-free DMEM 
containing 20 mM HEPES buffer, pH 7.4, and 0.5% (w/v) Albumax I. On day of assay, 
medium was replaced with serum-and inositol-free DMEM containing 25 mM LiCl and cells 
stimulated for 30 min with the indicated agonists. After medium removal, cells were lysed 
with 10 mM formic acid and lysates applied onto an anion exchange AG 1X-8 column, 
formate form, 200-400 mesh. The total IP fraction was then eluted with 2 M ammonium 
formate/formic acid buffer at pH 5 and radioactivity determined by liquid scintillation 
counting. 
2.6 Acceptor photobleaching Fluorescence Resonance Energy Transfer (FRET) 
FRET measurements were performed with the laser-induced acceptor bleaching method 
previously reported [26, 35]. This type of analysis employing antibodies on living cells 
instead of fused fluorescent reporters to label the FRET pair offers the unique advantage over 
conventional FRET of only assaying surface receptors. Briefly, following in vivo exposure 
with anti-tag antibodies, cells were fixed in 4% (w/v) p-formaldehyde, and stained with 
Alexa Fluor 488- (donor fluorochrome) or 555 (acceptor fluorochrome)-conjugated 
secondary antibodies. Three images were captured before bleaching in the 488 and 555 nm 
channels using the line-by-line sequential mode without any averaging steps to reduce basal 
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bleaching. Bleaching of the acceptor was performed within a region of interest (ROI) using 
30 pulses of the 555 nm laser line at 100% intensity (each pulse 1.28 sec/pixel). After 
bleaching seven images were acquired in the same channels to obtain a full curve for 
analysis. The number of bleaching steps was held constant throughout each experiment. 
FRET was quantified by measuring the average intensities of ROIs in the donor and acceptor 
fluorochrome channels before and after bleaching using the ImageJ software 
(http://rsbweb.nih.gov/ij/). To determine any change of fluorescence intensities not due to 
FRET occurring during the measurements, a distinct membrane ‘sentinel’ ROI of 
approximately the same size of the bleached ROI was measured in parallel, and all the results 
were normalized according to the background bleaching recorded in this sentinel ROI. Proper 
controls were performed to verify that no artifacts were generated in the emission spectra 
throughout the experimental setup due to sample overheating. Forty measurements from four 
different transfections were performed for each experimental condition. 
2.7 Data and statistical analysis 
All results are presented as means ± S.E. When indicated, ANOVA followed by post-hoc 
test for multiple comparisons was performed. Data from radioligand binding were evaluated 
by a nonlinear, least-squares curve-fitting procedure using GraphPad Prism version 5, 
implemented with the n-ligand m-binding site model, as described in the LIGAND computer 
program [36]. Concentration-response curves were evaluated using Prism 5, that uses the 
four-parameter logistic model as described in the ALLFIT program [37]. Parameter errors are 
all expressed as percentage coefficients of variation (%CV) and calculated by simultaneous 
analysis of at least three independent experiments performed in duplicate or triplicate. All 
parameter comparisons have been performed based on the F test for model comparison as 
implemented in GraphPad Prism. All curves shown are generated by computer fitting. 
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3. RESULTS 
3.1 Antagonist Binding and Receptor Expression  
To allow a proper comparison of receptor responses, transfection conditions were adjusted 
to ensure comparable levels of ectopic expression of WT and DDM (I25A, W29A, C35A, 
V36A, L39A, L43A, L44A, S47A mutant) of human TP  receptors in HEK293T cells in a 
range between 0.8-1.3 pmol/mg protein (Table 1). As expected, mock transfected cells 
showed no detectable binding to [3H]-SQ29,548, whereas analysis of binding curves of cells 
transiently transfected with WT TP  displayed a monophasic behavior corresponding to a 
single-site model by computer fitting (Fig. 2A), with binding parameters as previously 
reported [31, 32, 34]. The TP DDM displayed a binding affinity not statistically different 
from the corresponding WT receptor (Table 1). These results strongly indicate that DDM, is 
trafficked to the cell surface (Fig. 2B), can be expressed at physiological relevant levels and 
exhibits an overall conformation and folding not significantly different from that of WT. 
3.2 Effect of TM1 mutations on homo-dimerization of TP  receptor 
We previously reported that WT TP  and TP  form hetero-dimers through contacts 
between hydrophobic residues of TM1 with mutations in the TM1 stretch impairing TP -
TP  association regardless of which TP member of the co-transfected pair contains the 
mutated residues [26]. To confirm that the TP  DDM is impaired in homo-dimer formation. 
we co-expressed WT and DDM mutant TP  tagged with an N-terminal myc epitope in 
HEK293T cells. Western blotting revealed distinct bands migrating on SDS-PAGE at the 
relative molecular masses (Mr) predicted for monomeric and dimeric receptors for WT 
transfectants Fig. . Interestingly, unlike the WT most of the DDM exists as a 
monomer.  There was a significant reduction of the density of the dimeric band in DDM 
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accompanied by increased intensity of monomeric bands referred to as glycosylated and non-
glycosylated TP monomers as previously reported [25] (p < 0.001, Fig. 3B).  
To obtain direct evidence that mutations in the TM1 interface of DDM impair TP  
dimerization, we performed FRET analysis using the laser-induced acceptor photobleaching 
method [35]. In this type of analysis fluorescence emission by a donor fluorochrome is 
quenched due to direct transfer of excitation energy to an acceptor fluorochrome. Upon laser-
induced acceptor fluorochrome bleaching this FRET is blunted and the donor signal is de-
quenched. Accordingly, HEK293T cells co-transfected with different TPα pairs, tagged with 
HA and c-myc epitopes, were in vivo labeled with their corresponding anti-tag antibodies, 
fixed, subjected to indirect immunofluorescence and then imaged by laser scanning confocal 
microscopy. Figure 3C demonstrates our approach. Note that an increase of fluorescence 
signal emitted by the donor fluorochrome resulting from de-quenching (i.e. FRET efficiency) 
is only present in analyzed cells co-expressing the WT TP pair, whereas no increase 
occurs in the DDM expressing cells. 
To further characterize this phenomenon we repeated the experiments by transfecting cells 
with different levels of the TP  DNA (500, 5 and 0.5 ng) (Fig. 3D). Even at the highest 
levels of DDM receptor expression we could still not detect any interaction between receptor 
monomers although we could clearly visualize both tagged versions of the receptor at the cell 
surface (Fig. 2B). These results suggest that homo-dimerization of TP  within a large range 
of expression levels, including physiological ones (corresponding to the intermediate level 
[38], is strongly destabilized in the receptor bearing TM1 mutations. 
3.3 Basal Activity of DDM receptor in the presence of overexpression of G q 
A key feature of the TP receptor is a lack of constitutive activity (CA), even following 
increased expression of receptor, G q, or a combination of both [31, 34]. To further assess 
the pharmacological characteristics of the DDM receptor, its basal activity was compared 
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with that of the WT by assaying total IP production in the absence of agonist stimulation 
(Fig. 4). These experiments were also repeated in the presence of G q overexpression to try 
and promote CA at these receptors. In the mock condition, a 5-fold overexpression of G q 
induced an increase of total IP production (about 50% compared to no G q, Fig. 4), likely 
due to a general increase in this G protein as previously reported [34]. Co-expression of 
either the WT or DDM failed to further enhance total IP production. These results show that 
the DDM, like the WT and other TP receptor mutants tested thus far, does not show any 
appreciable CA [31, 32, 34]. 
3.4 Pharmacological characterization of the DDM functional activity 
To fully characterize DDM activity, IP accumulation was evaluated in HEK293T cells 
transiently expressing WT or DDM in response to a series of pharmacodynamically different 
TP agonists, including the full agonists U46619 and I-BOP and the partial agonists 8-iso-
PGF2  and 8-isoPGE2 (Fig. 5A, B). Computer-assisted analysis of concentration-response 
curves showed that EC50 values for the different agonists at DDM were significantly shifted 
rightward as compared to WT (p < 0.01; Table 2). 8-iso-PGF2  and 8-isoPGE2 activated the 
DDM and the WT with equal efficacies, in accordance with their pharmacodynamic profiles 
as partial agonists (Fig. 5A, B). 
We also assessed the ability of the TP receptor antagonist SQ29,549 and the structurally 
unrelated TP and DP2 antagonist ramatroban, to inhibit agonist (U46619 (1 µM )-induced IP 
production by WT and DDM receptors ; Fig. 5C, D). Both antagonist inhibition curves at the 
DDM were significantly (p < 0.01) leftward shifted with IC50 values around 5-6 fold lower 
than the WT (IC50 = 254 nM ± 66 %CV and 144 ± 29 %CV for SQ29,548 and ramatroban, 
respectively, for WT vs. 45 nM ± 61 %CV and 29 ± 56 %CV for SQ29,548 and ramatroban, 
respectively, for DDM). This apparent increase in antagonist potencies is likely a 
consequence the reduced potency of U46619 to activate DDM. Collectively, these data 
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indicate that the DDM form of TP  less efficiently responds to agonist activation across a 
panel of compounds endowed with different intrinsic activities than the WT homo-dimeric 
form. 
To confirm that the pharmacological profile of our artificial DDM is not due exclusively to 
the presence of the eight mutations in TM1, we co-transfected the WT TP receptor with a 
truncated form of TP coding only for the N terminal and TM1 regions (TPtrunc), an approach 
previously shown to destabilize the quaternary structure and the interaction interfaces of 
rhodopsin [39]. While TPtrunc alone was pharmacologically silent, co-transfection with the 
WT TP receptor reduced receptor function (Fig. 6A). Close examination of dose response 
curves revealed that WT TP receptor plus TPtrunc produced a receptor profile similar to 
DDM with potencies (EC50 = 84.8 nM ± 50 %CV and 111 nM ± 72 %CV, respectively) and 
efficacies not statistically different. Notably, TPtrunc is expressed at cellular surface and 
laser-induced acceptor bleaching FRET demonstrated that it is able to dimerize with WT TP 
receptor (Fig. 6B). Thus, we can assume that the presence of an excess (1:10) of TPtrunc 
interfere with the WT-WT TP dimer formation, forcing WT TP receptor into a monomeric 
form. This, in turn, suggests that the pharmacological profile observed for the DDM might 
indeed be due to its monomeric state and not to merely the presence of mutations. It is likely 
that TPrunc interferes with the quaternary structure of the homo-dimer, but do not necessarily 
block dimerization completely. 
Transfection of a mutated form of the TPtrunc (carrying the same eight mutations as the 
DDM, TPtrunc TM1) with the WT TP receptor (Fig. 6A) resulted in concentration response 
curve identical to that of WT TP alone (EC50 = 23.2 nM ± 27 %CV and 35.6 nM ± 31 %CV, 
respectively) demonstrating the specificity of the functional interference exerted by the 
truncated form of the receptor on TP dimers/oligomers and the importance of these eight 
amino acids in TM1 to WT TP receptor interaction. 
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3.5 Ligand binding profile of the DDM receptor 
The ligand binding capacities of the WT and DDM receptors transiently expressed in HEK-
293T cells were also tested to assess whether the ligand binding pocket and/or the active 
receptor conformation was affected by mutations. Heterologous competition curves 
performed with [3H]-SQ29,548 and several unlabeled agonists revealed unchanged affinities 
between both WT and DDM receptor constructs  and an entire panel of compounds, including 
the two partial agonists 8-iso-PGF2  and 8-isoPGE2 (Fig. 7A, B and Table 3). In addition to 
SQ29,548 (Table 1), also the structurally unrelated TP antagonist, PTA2 (Fig. 7C and D) did 
not show any difference in binding affinities between receptors (Ki = 3.6 M ± 68 %CV and 
Ki = 2.4 M ± 67 %CV for WT and DDM, respectively). These data, therefore, are 
consistent with similar agonist-induced receptor conformations and G protein coupling for 
both WT and DDM, suggesting that the difference in signaling efficiency might be due to a 
difference in G protein activation, rather than to a difference in receptor conformational 
states. 
3.6 Impact of W29C and N42S mutations on dimerization and pharmacology of TP  
receptor 
As mentioned above a patient heterozygous for the TP receptor variant W29C with 
impaired platelet response to TP receptor agonists has been previously identified [23]. In this 
study in HEK293T U46619 was demonstrated to be less potent at the W29C variant versus 
WT in inducing a rise of cytosolic free Ca2+, although the molecular mechanisms underlying 
this difference were not fully elucidated [23]. Importantly W29 is one of the eight residues 
mutated in our DDM [26] (Fig. 1). In order to study the impact of the single W29C mutation 
on dimerization of TP receptor, the endogenously expressed receptor in platelets was detected 
with an antibody directed against the carboxyl-terminal of human TP  receptor. The TP 
receptor can be found in monomeric, dimeric and higher oligomeric forms in human platelets 
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from healthy donors (Fig. 8A, HD) [25]. Platelets from the W29C patient show only a modest 
reduction of the dimeric TP form (Fig. 8A, W29C), although quantification over multiple 
experiments seems to suggest a decrease of both dimeric and oligomeric forms (Fig. 8B) of 
receptor, which, however, did not reach statistical significance. These results were not totally 
unexpected, considering that the patient is heterozygous for the W29C mutation [23], and 
therefore may still be able to express a substantial amount of dimeric WT TP. To further 
investigate the functional significance of the W29C mutation, we again used laser-induced 
acceptor bleaching FRET methodology outlined above on transfected HEK 293T cells. 
Intriguingly there was no recovery of donor fluorescence due to a lack of energy transfer in 
cells overexpressing the WT-W29C pair (103% ± 0.8 SE, Fig. 9A and B), suggesting 
minimal proximity and hence less dimerization between donor/acceptor proteins. Similar data 
were also obtained when we tested another naturally occurring mutation, N42S [24] with 
minimal evident energy transfer in our FRET studies (Fig 9B). It should be noted that this 
residue is just one upstream of the L43 and L44 residues mutated in our DDM (Fig. 1), a 
difference that might be due to the fact that we do not have a crystal structure of our receptor, 
but only an homology model [26]. Collectively, these results strongly suggest that TP  
dimerization is impaired with W29C or the N42S receptor variant, in striking agreement with 
the behavior of our artificial DDM. 
We therefore further investigated the pharmacological profile of the W29C natural variant in 
functional assays (Fig. 9C). Concentration-response curves of all agonists for W29C were 
significantly shifted rightward as compared to WT, with calculated potencies (EC50 = 159 nM 
± 21 %CV and 63 ± 9 %CV for U46619 and I-BOP, and EC50 = 1896 nM ± 37 %CV and 
43280 ± 56 %CV for 8-iso-PGE2 and 8-isoPGF2 , respectively) consistent with those of the 
artificial DDM (Table 2). Interestingly, the pharmacological profile of the naturally occurring 
W29C mutant exactly matches that of the artificial DDM. Additionally, 8-iso-PGF2  and 8-
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isoPGE2 also confirmed their pharmacodynamic profile as partial agonists activating the 
W29C variant with equal efficacies (Emax = 3.2 ± 5 %CV and 3.6 ± 16 %CV, respectively). 
The antagonists SQ29,548 and ramatroban specifically inhibited U46619-induced total IP 
production by W29C with results not statistically different from DDM (data not shown).  
 
4. DISCUSSION 
Despite the intense effort devoted to demonstrate the mechanism(s) by which GPCRs form 
complexes with each other, the physiological relevance of this phenomenon still remains 
elusive [11, 15] [16]. Hetero-dimerization has been shown to be an absolute requirement for 
the activity of some Class C GPCRs [13, 14] and the cell-surface delivery of other GPCRs 
[40, 41]. The process can also be regarded as a way of creating a receptor complex endowed 
with unique signaling features in response to the binding of specific ligands [42, 43]. A more 
difficult point to characterize is the role of receptor homo-dimerization in terms of receptor 
activation and function. In order to address this question we characterized the 
pharmacological activity of the human TP receptor, containing either artificial (DDM TP) 
[26] or naturally occurring (W29C and N42S) [23, 24] mutations in TM1, impaired in its 
ability to spontaneously form receptor dimers.  
The main key finding of the present study comes from the detailed pharmacological 
characterization of the DDM TP receptor using a combination of antagonists and full and 
partial agonists in living cells. Unlike the WT receptor which spontaneously forms homo-
dimers at physiological expression levels, DDM, which is significantly impaired in its ability 
to form dimers, displays a significant reduction in agonist potency in comparison to the WT. 
Beyond a reduction in agonist potency, the WT and DDM receptors have indistinguishable 
overall and active conformations as assessed by antagonist and agonist ligand-binding studies 
and possess similar abilities to bind and induce Gq-mediated signaling. Thus, TM1 appears to 
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be an important region contributing to the normal function of the TP  receptor in vitro. To 
support these findings two recent studies examining naturally occurring variants in the TP  
receptor, W29C and N42S identified in two patients with bleeding disorders, demonstrated 
that platelets from these patients exhibited a decrease in TP receptor-stimulated activation. 
We now demonstrate that both W29C and N42S TP  receptor variants are impaired in their 
ability to dimerize in a recombinant system, and with a partial reduction also apparent in 
platelets from these patients. Strikingly, one of these naturally occurring mutations (W29C) 
exactly matches, and the other (N42S) is just one residue upstream of two out of the eight 
residues mutated in our artificial DDM. Thus, we suggest that a single mutation in TM1 
might be sufficient to impair homo-dimer formation, and may in part be responsible for the 
observed decrease in TP receptor functionality observed in vivo. 
Although DDM is expressed at the cell surface at physiologically relevant levels it is 
drastically impaired in its tendency to form homo-dimers over a range of different expression 
levels, as demonstrated by western blotting and acceptor photobleaching FRET analysis. 
Ligand-binding studies with the TP receptor antagonist SQ29,548 confirm normal protein 
folding, and suggest a conserved overall protein conformation, as also previously postulated 
by molecular dynamic simulations [26]. 
In functional assays DDM signaling was significantly impaired versus WT with a 
significant rightward shift in agonist-potency across a panel of full and partial TP receptor 
agonists. In agreement with this loss of agonist activity, two structurally different antagonists 
demonstrated an apparent increase in their potency. Most importantly, despite their reduced 
potency in promoting DDM activation, all the ligands investigated retained their respective 
pharmacological profiles as either full or partial agonists. In addition, the basal activity of 
DDM is similar to that of WT and not affected by increased expression of its cognate G 
protein, a further validation of TP ‘resistance’ to CA [31, 32, 34].  
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Importantly, co-transfection of the WT TP receptor with a truncated form of TP coding only 
for the N terminal and TM1 regions produced a pharmacological profile similar to that of the 
DDM. Because TPtrunc is able to dimerize with WT receptor, its co-expression very likely 
impairs WT-WT TP dimer formation, forcing TP receptor into a monomeric form. This, in 
turn, suggests that the monomeric form of TP, as for many other GPCRs, is able to signal, 
and that the pharmacological profile observed for the DDM might indeed be due to its 
monomeric state and not to merely the presence of mutations. 
In addition, the phenotype described for this ‘artificial’ DDM matches the phenotypes of the 
W29C and N42S TP  natural variants [23, 24]. In these studies we suggested that reduced 
TP receptor surface expression seen in the W29C patient reduced TP receptor-stimulated 
platelet aggregation. We now speculate that in addition to this reduction in surface 
expression, since both the W29C and N42S are impaired in the dimerization with WT, the 
heterozygous patients may also display a shift in the normal equilibrium from TP  homo-
dimers to monomers with a consequent overall decrease in agonist potency. Western blotting 
of patient platelets TP  reveals receptor in monomeric, dimeric, and higher-order oligomeric 
forms in agreement with previously published results [25]. These blots suggested that there 
maybe a modest reduction in TP oligomer although it should be noted that both patients 
are heterozygous for each variant and therefore will also express WT TP receptor. The 
presence of WT TP receptor is likely to mask our ability to see a statistically significant 
reduction in dimer formation. Intriguingly, each of these variants shows comparable levels of 
maximal receptor responsiveness to agonists when compared to WT, but have reduced 
potency in second messenger production [23, 24], as it is the case for the artificial DDM. It is 
therefore tempting to speculate that the impairment in dimer formation might represent a 
crucial molecular mechanism of the decreased platelet response to TP agonists in vivo. 
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In an attempt to clarify whether the change in agonist potency might arise from a change in 
the ligand-binding pocket and/or in an allosteric effect within the protomers of the TP  
homo-dimer [44], we analyzed the agonist binding profile of a series of compounds endowed 
with different intrinsic activities. All the tested agonists displayed equal binding affinities for 
the DDM and WT receptors, thus indicating that the agonist-induced active state of the 
monomeric and dimeric proteins are similar, and supporting the absence of any allosteric 
modulation across protomers of the TP  homo-dimer at the level of the binding pocket. 
Notably, the DDM retains high affinity agonist binding that is indicative of a normal coupling 
with the cognate G proteins. Thus, differences able to explain a reduced potency of agonists 
in DDM activation must be sought downstream of the TP receptor itself, likely at the G 
protein level. 
Collectively, all these observations strongly support the notion that reduced agonist 
potencies demonstrated by the DDM in second messenger production do not arise from a 
change in the receptor state, i.e. by a variation in agonist-induced conformation, or in the 
receptor ability to recognize pharmacodynamically different agonists or in its ability to 
interact with G proteins. Rather, these data are suggestive of a reduced signaling strength, 
likely due to a reduced efficiency in G protein activation. While we recognize that we cannot 
completely rule out the possibility that the differences observed in our DDM might depend 
upon the presence of the mutations alone, the fact that a single mutation (W29C or N42S) or 
dimerization with a truncated and silent form of the receptor closely match the pharmacology 
of our DDM, convincingly indicates that the particular pharmacological profile observed with 
our TP mutants may be the result of an impairment of dimer/oligomer formation.  
In respect to this, contrasting data are emerging on G protein activation by different dimeric 
GPCRs. Some data support a model of a higher efficiency of G protein activation in 
dimers/oligomers [29, 45, 46], whilst others demonstrate a similar degree of activation [6, 7], 
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or even a reduced G protein coupling efficiency by dimeric ensembles [9, 10]. While it is 
possible that different receptors might simply behave differently from another, it is also true 
that the same receptor seems to behave differently in different experimental conditions as 
shown with rhodopsin isolated by filtration techniques [29] versus expression in a 
phospholipid bilayer [7]. To our knowledge, our functional results are the first to be obtained 
with a dimeric and a monomeric form of a Class A GPCR expressed in living cells that is not 
artificially purified/reconstituted. More data on other receptor systems will certainly come in 
the near future to clarify this issue, as it has been recently the case for the glucagon-like 
peptide-1 receptor, where homo-dimer formation seems important for the control of signal 
bias [47]. 
Finally, while the stoichiometry of the receptor-G protein unit still remains an open 
question, a number of studies favor a 2:1 stoichiometry, corroborating the hetero-pentameric 
structure of two protomers binding one heterotrimeric G protein [46, 48-51]. A number of 
biochemical studies suggest the involvement of several distinct G protein regions in receptor 
interaction [52], both on the  [53, 54], as well as on the -subunit [55, 56]. While the C-
terminal sites on the -subunit have been confirmed by crystallization to interact with 
opsin/metarhodopsin [57] and 2-AR [58], unexpectedly, no direct interaction between 2-
AR and G - or G -subunits have been detected [58]. Indeed biochemical studies suggest 
that 2-AR exists as a dimer in living cells [59] and that the C-terminal of Gα and of Gγ are 
further apart in the G protein heterotrimer than the width of a monomeric GPCR [60]. In 
addition, the 2:1 stoichiometry is consistent with multiple contact sites of the G protein with 
two different protomers [61, 62] whereas the heterotrimer appears necessary for efficient 
coupling to a GPCR [63]. In light of our data and of this ‘double docking’ model described 
above we can speculate that, when a secondary site of contact is available due to the presence 
of a homo-dimer, a stronger coupling with the cognate G protein is favored, hence more 
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efficient signaling is then possible. Indeed, the presence of transducin has been shown to 
stabilize the dimeric conformation of rhodopsin, while the presence of synthetic peptides that 
disrupt rhodopsin dimerization, similar to our truncated TP receptor construct, inhibited such 
stabilization [39]. 
In conclusion, our data propose that TP  receptor dimer formation favors a more efficient 
signaling complex, increasing agonist potency. This augmented ability maybe as the result of 
a more efficient G protein activation. Given that TP monomers and homo-dimers are, 
presumably, in equilibrium at steady state [64, 65], it is likely that when a single TP  
protomer makes a complex with a TP  [25, 26] or IP protomer [27] there would be a shift in 
the equilibrium from TP  homo-dimers to monomers with a consequent overall decrease in 
agonist potency, which may be important in thrombosis-related diseases. In this respect, the 
impairment of W29C and N42S to form dimers with WT receptor may represent one 
molecular mechanism through which platelet TP receptor dysfunction affects the patient(s) 
carrying these mutations. 
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Table 1. Binding affinities of [3H]SQ29,548 in HEK293 cells transiently expressing the WT 
or mutant human TP receptors. Binding affinities and capacities were obtained by 
simultaneous analysis of at least six independent mixed-type experiments, each performed in 
duplicate (see Materials and Methods). 
 
Receptor Kd, 
nM ± %CV 
Bmax, 
pmol/mg prot ± %CV 
WT 6.1 ± 30 0.85 ± 47 
DDM 7.6 ± 28 1.3 ± 38 
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Table 2. Total IP dose-response parameters for different agonists in HEK293T cells 
transiently expressing the WT or DDM receptors. Values of EC50 and Emax were obtained by 
simultaneous analysis with GraphPad Prism of at least three independent experiments each 
performed in duplicates or triplicates.  
 
 
 WT DDM 
Agonist EC50, 
nM ± %CV 
Emax, 
fold increase ± 
%CV 
EC50, 
nM ± %CV 
Emax, 
fold increase ± 
%CV 
U46619 45 ± 31 8.1 ± 4.5 270 ± 23** 7.7 ± 4 
I-BOP 17.6 ± 29 7.3 ± 5 110 ± 54** 6.7 ± 12 
8-isoPGE2 702 ± 82 2.8 ± 14§ 5400 ± 85** 2.8 ± 14§ 
8-
isoPGF2  
5361 ± 93 2.7 ± 13§ 32400 ± 89** 2.7 ± 13§ 
     ** p< 0.01 vs. WT 
§ shared parameters 
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Table 3. Agonist affinities for the receptor binding site labeled by [3H]SQ29,548 in 
HEK293T cells transiently expressing the WT or the DDM receptors. Kd/i values were 
obtained by simultaneous analysis of at least three independent experiments analyzed with 
GraphPad Prism implemented with the LIGAND model (see under Experimental 
procedures). 
 
 
Agonist 
WT 
Kd/i, nM ± %CV 
DDM 
Kd/i, nM ± %CV 
U46619 199 ± 13 404 ± 24 
I-BOP 23 ± 30 37 ± 30 
8-isoPGE2 4296 ± 35 2838 ± 41 
8-isoPGF2  16900 ± 38 34360 ± 64 
 
Table 4. BRET concentration-response parameters for U46619-induced G protein activation 
in HEK293T cells transiently expressing the WT or different TPα receptor mutants. Values of 
EC50’s and Emax’s were obtained by simultaneous analysis with GraphPad Prism (see 
Section 2) of at least three independent experiments each performed in triplicates. 
 EC50, nM ± %CV Emax, ± %CV 
WT 29.9 ± 28 −0.12 ± 4 
DDM 161 ± 36⁎⁎ −0.095 ± 5 
N42S 94.5 ± 15⁎⁎ −0.13 ± 3 
W29C 247 ± 19⁎⁎ −0.13 ± 4 
⁎⁎ 
p < 0.01 vs. WT. 
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LEGEND TO THE FIGURES 
 
FIGURE 1. Predicted dimeric model of TP . 
Representation of the predicted dimeric interface of TP  seen from the intracellular side in a 
direction parallel to the membrane surface. For the sake of clarity only TM1 is shown. The 
side chains of the TM1 interface amino acids subjected to alanine substitutions are shown in 
gray. 
 
 
 
FIGURE 2. [3H]SQ29,548 binding curves of of TP  WT and TP  DDM and mutant 
surface expression in HEK293T cells. 
Panel A. [3H]SQ29,548 binding studies in HEK293T cells transiently expressing the WT (◼) 
or DDM () of human TPa receptor. Mixed type curves were performed at 25°C with 30 
min incubation. Binding is expressed as the ratio of bound ligand to total ligand 
concentrations (B/T, dimensionless) versus the logarithm of total unlabeled ligand 
concentration (Log T). Non-specific binding was calculated by computer as one of the 
unknown parameters of the model and was always <10% of total binding. Curves are 
  34 
computer generated from the simultaneous analysis of at least six experiments, each in 
duplicate. Values for Kd/i are shown in Table 1. Panel B. Representative images of 
fluorescent signals emitted by donor (500 ng DNA HA-TP DDM; green) and acceptor (500 
ng DNA Myc- TP DDM red) fluorochromes in two contiguous HEK293T cells expressing 
TP  DDM mutant. 
 
 
FIGURE 3. Western blotting and acceptor photobleaching FRET analysis of HEK-293T 
cell transiently transfected with either TP WT or DDM mutant. 
Panel A shows one representative analysis of eight independent western blots. Histograms in 
Panel B show the densitometric analysis of bands referred to mono- and dimeric Myc-tagged 
WT and DDM mutant receptors performed with ‘gel analizer’ ImageJ’ plugin. The results are 
expressed as relative over total intensities of each single lane. Comparison of multiple groups 
performed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test 
reveals a statistically significant decrease in the dimeric and an increase in the monomeric 
form of DDM compared to TP WT (***p<0.001). Error bars represent the means ± SE of 
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at least three independent experiments. Panel C and D. HEK293T cells co-transfected with 
TP WT or DDM mutant, tagged with two different epitopes were labeled in vivo with 
the corresponding anti-tag antibodies. After fixation cells were subjected to indirect 
immunofluorescence with Alexa Fluor 488- (donor fluorochrome) or 555 (acceptor 
fluorochrome)-conjugated secondary antibodies and imaged with laser scanning confocal 
microscopy. Panel C show representative images of fluorescent signals emitted by donor (2.5 
ng DNA HA-TP green and acceptor 2.5 ng DNA Myc-
TP red fluorochromes in two contiguous HEK293T cells expressing WT HA-
TP and Myc-TP pairs before and after laser-induced photobleaching of acceptor 
fluorescence in a defined plasma membrane region of interest (ROI; dotted line). Panel D 
show the quantitation of average percent donor and acceptor fluorescence intensities of WT 
and DDM mutant HA-TP  and Myc-TP , respectively, normalized for unbleached 
‘sentinel’ plasma membrane ROIs (broken lines in panel A). No statistically significant 
differences were observed in acceptor recovery (i.e. FRET signal) comparing the three 
different levels of expression transfected (⚫ 500 ng, ◼ 5 ng,  0.5 ng cDNA). The decrease 
in WT and DDM Myc-TP acceptor signals are not significantly different. Statistical 
analysis of immunofluorescence data was performed using one-way ANOVA repeated 
measurements with one grouping factor for all frames. Data are expressed as the means ± SE 
of 10 different fields from three independent experiments. Scale bar = 10 m. 
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FIGURE 4. Basal activity in HEK293T cells transiently expressing TP  WT or DDM 
mutants in the absence and presence of G q overexpression. 
Total IP accumulation in basal conditions (white bars) and in the presence (black bars) of 
G q overexpression (TP  and G q plasmids were added in a 1:5 ratio (5xGq). Data are 
expressed as dpm/well. Error bars represent the means ± SE of at least three independent 
experiments each performed in duplicates or triplicates.  
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FIGURE 5. IP dose-response curves in HEK293T cells transiently expressing equal 
amounts of the WT (A and C) or DDM (B and D) of human TP  receptor. 
Panel A. Agonist-induced total IP accumulation in HEK293T cells was measured after 
incubation in the absence (basal) or presence of increasing concentrations of the indicated 
agonists for 30 min. Panel A and B. Agonist-induced effects ( U46619,  I-BOP, ⚫ 8-
isoPGE2,  8-iso-PGF2 ). Panels C and D. Antagonist induced-effects (◼ SQ29,548,  
Ramatroban). Data are expressed as fold increase over basal. Curves are computer-generated 
from the simultaneous analysis of at least three independent experiments each performed in 
duplicates or triplicates. Error bars represent the means ± SE. Values for EC50s and 
significant differences from WT are shown in Table 2. 
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FIGURE 6. IP dose-response curves (A) and acceptor photobleaching FRET analysis 
(B) of HEK293T transiently expressing WT, DDM or TPtrunc of human TP  receptor. 
Panel A. Agonist-induced total IP accumulation was measured after incubation in the 
presence of increasing concentrations of U46619 in HEK293T cells transfected with (◼) 
TP  WT, () DDM, (⚫) TP  WT + TPtrunc, () TP  WT + TPtrunc TM1 and () 
TPtrun alone. TPtrunc TM1 represents the truncated form of TP carrying the same eight 
mutations as DDM. Data are expressed as fold increase over basal. Curves are computer-
generated from the simultaneous analysis of at least three independent experiments each 
performed in duplicates or triplicates. Error bars represent the means ± SE. Panel B. The 
graph show the quantitation of average percent donor and acceptor fluorescence intensities in 
HEK293T transfected with TP  couples (◼ WT/WT,  WT/DDM and ⚫ WT/TPtrunc 
respectively) with a 1:1 DNA ratio, normalized for unbleached ‘sentinel’ plasma membrane 
ROIs in acceptor photobleaching FRET assays. No statistically significant differences were 
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observed in acceptor recovery (i.e. FRET signal) comparing the WT/WT and WT/TPtrunc 
samples while, as previously observed, WT/DDM couple do not show any significant FRET 
signals. Statistical analysis data was performed using one-way ANOVA repeated 
measurements with one grouping factor for all frames. Data are expressed as the means ± SE 
of 10 different fields from three independent experiments.  
 
 
FIGURE 7. Ligand binding profile of WT and DDM of human TP  receptor 
Agonist binding studies in HEK293T cells transiently expressing the WT (A and C) or DDM 
(B and D) of human TP  receptor. For each construct, cold SQ29,548(◼), U46619(), I-
BOP(), 8-isoPGE2(⚫) or 8-isoPGF2 ) or PTA2() were used in competition against 
1 nM [3H]SQ29,54. Mixed type curves and heterologous competition curves were performed 
at 25°C with 30 min incubation. Binding is expressed as the ratio of bound ligand to total 
ligand concentrations (B/T, dimensionless) versus the logarithm of total unlabeled ligand 
concentration (Log T). Non-specific binding was calculated by computer as one of the 
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unknown parameters of the model and was always <10% of total binding. Curves are 
computer generated from the simultaneous analysis of at least three independent mixed-type 
and heterologous competition experiments, each in duplicate. Values for Kd/i are shown in 
Table 2. 
 
 
FIGURE 8. TPα receptor expression in human platelets. 
Total TP receptor expression was assessed in platelets from healthy donors (HD) or a patient 
expressing the W29C-TPα (W29C) variant by immunoblotting with a receptor specific 
antibody. Panel A. Representative blot of four independent experiments. Equal loading was 
confirmed by assessing tubulin levels (lower blot). Panel B. Densitometric analysis of bands 
referred to as monomer, dimer and oligomer as assessed using ImageJ software. Data are 
expressed as band density (band density - background). Comparison of multiple groups 
performed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test. 
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FIGURE 9. Acceptor photobleaching FRET analysis of HEK293T cells transiently 
expressing WT-WT, WT-W29C or WT-N42S HA- and FLAG-tagged TP  pairs and IP 
dose-response curves for W29C receptor variant 
Panel A and B. HEK293T cells co-transfected with different TPα pairs, tagged with HA and 
FLAG epitopes, were in vivo labeled with the corresponding anti-tag antibodies. After 
fixation, cells were subjected to indirect immunofluorescence with Alexa Fluor 488- (donor 
fluorochrome) or 555 (acceptor fluorochrome)-conjugated secondary antibodies and imaged 
with laser scanning confocal microscopy. Panel A shows representative images of fluorescent 
signals emitted by donor (green) and acceptor (red) fluorochromes in two contiguous 
HEK293T cells expressing WT FLAG-TPα and HA-TPα pair before and after laser-induced 
photobleaching of acceptor fluorescence in a defined plasma membrane region of interest 
(ROI; dotted line). Panel B shows the histogram of the quantitation of average percent donor 
fluorescence intensities of WT-WT, WT-N42S or WT-W29C TPα pairs, normalized for 
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unbleached ‘sentinel’ plasma membrane ROIs after laser-induced photobleaching of acceptor 
fluorescence. Statistical analysis of immunofluorescence data was performed using one-way 
ANOVA repeated measurements with one grouping factor (**p < 0.01; n=40, 4 independent 
experiments). Data are expressed as the means ± SE of ten different fields from four 
independent experiments. Scale bar: 10 M. Panel C. Agonist-induced total IP 
accumulation in HEK293T cells was measured after incubation in the absence (basal) or 
presence of increasing concentrations of the indicated agonists for 30 min ( U46619,  I-
BOP, ⚫ 8-isoPGE2,  8-iso-PGF2 ). Data are expressed as fold increase over basal. Curves 
are computer-generated from the simultaneous analysis of at least three independent 
experiments each performed in duplicates or triplicates. Error bars represent the means ± SE. 
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Fig. 10. IP dose-response curves in HEK293T cells transiently expressing equal amounts of 
the WT, W29C or N42S mutants of human TPα receptor. Agonist-induced total IP 
accumulation in HEK293T cells was measured after incubation in the absence (basal) or 
presence of increasing concentrations of the indicated agonists for 30 min (Panel A ■,□ 
U46619, ●,○ I-BOP; Panel B ♦,♢ 8-isoPGE2, ▲,△ 8-iso-PGF2α). Data are expressed as fold 
increase over basal. Curves are computer-generated from the simultaneous analysis of at least 
three independent experiments each performed in duplicates or triplicates. Error bars 
represent the means ± SE. 
 
 
Fig. 11. BRET2 measurement of Gαqβ1γ2 complex activation in HEK293T cells expressing 
equal amounts of WT, DDM, W29C or N42S mutants of human TPα receptor. A and B. 
BRET was measured in HEK293T cells co-expressing Gαq-Rluc8 together with GFP10-
Gγ2 and Gβ1 in the presence of WT (■), DDM (□) N42S (△) or W29C (∇) mutants of the 
human TPα receptor and stimulated with increasing concentrations of U46619 for 2 min. 
Results are indicated as BRET ligand effect that has been calculated as the differences in the 
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BRET signal measured in the presence and the absence of the agonist, and are expressed as 
the mean value ± SE of at least three independent determinations. Values for EC50′s and 
significant differences from WT are shown in Table 4. 
 
